P/E ratio for Imunon (IMNN)
P/E ratio as of June 2024 (TTM): -0.2905
According to Imunon's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.290451. At the end of 2022 the company had a P/E ratio of -0.2611.
P/E ratio history for Imunon from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.2611 | -80.95% |
| 2021 | -1.37 | 29.78% |
| 2020 | -1.06 | -53.07% |
| 2019 | -2.25 | 3.72% |
| 2018 | -2.17 | 292.64% |
| 2017 | -0.5525 | 55.61% |
| 2016 | -0.3550 | -80.58% |
| 2015 | -1.83 | 7.52% |
| 2014 | -1.70 | -55.84% |
| 2013 | -3.85 | -64.14% |
| 2012 | -10.7 | 613.88% |
| 2011 | -1.50 | 11.44% |
| 2010 | -1.35 | -41.02% |
| 2009 | -2.29 | 20.57% |
| 2008 | -1.90 | -309.45% |
| 2007 | 0.9064 | -133.84% |
| 2006 | -2.68 | -46.48% |
| 2005 | -5.01 | -22.81% |
| 2004 | -6.48 | -40.67% |
| 2003 | -10.9 | 179.26% |
| 2002 | -3.91 | -40.77% |
| 2001 | -6.61 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.